European competition laws are aimed at preventing companies from using a dominant market position to impose excessive prices (1). Companies suspected of breaking these rules after an investigation are able to propose a set of corrective commitments, which the European Commission can accept and make binding (1). In 2021, a first sanction of this type was applied against the South African pharmaceutical company Aspen, which has committed to reducing the price of six cancer drugs in the European Union, by 73% on average. It has also promised to guarantee the supply of these drugs until 2025, and to continue to supply them for an additional 5-year period unless it has relinquished its marketing authorisations in the meantime (2).
展开▼
